In 2015, the FDA approved two PCSK9 inhibitors, Alirocumab and Evolocumab, for adults with familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who need further LDL-C reduction [5,6]. Here, PCSK9 is linked to familial hypercholesterolemia.